Garde Capital Inc. reduced its position in Pfizer, Inc. (NYSE:PFE) by 11.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,927 shares of the biopharmaceutical company’s stock after selling 1,604 shares during the period. Garde Capital Inc.’s holdings in Pfizer were worth $408,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Asset Planning Services Ltd. raised its position in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares during the last quarter. Orrstown Financial Services Inc. raised its position in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares during the last quarter. Cable Hill Partners LLC raised its position in Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 265 shares during the last quarter. D Orazio & Associates Inc. raised its position in Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 28 shares during the last quarter. Finally, Acropolis Investment Management LLC raised its position in Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 100 shares during the last quarter. 69.94% of the stock is owned by hedge funds and other institutional investors.

Pfizer, Inc. (NYSE PFE) traded up 0.42% during midday trading on Tuesday, reaching $33.45. The company’s stock had a trading volume of 4,451,261 shares. Pfizer, Inc. has a one year low of $29.83 and a one year high of $35.38. The firm has a 50 day moving average price of $33.38 and a 200 day moving average price of $33.35. The firm has a market cap of $199.62 billion, a P/E ratio of 24.47 and a beta of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The business had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the prior year, the firm earned $0.64 EPS. The business’s revenue was down 1.9% on a year-over-year basis. Equities research analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.84%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio is 94.12%.

COPYRIGHT VIOLATION WARNING: “Garde Capital Inc. Has $408,000 Stake in Pfizer, Inc. (PFE)” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.watchlistnews.com/garde-capital-inc-has-408000-stake-in-pfizer-inc-pfe/1490968.html.

A number of equities analysts have recently commented on the company. Berenberg Bank set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Tuesday. Cowen and Company set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. UBS AG reaffirmed a “buy” rating and issued a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. Finally, Jefferies Group LLC reissued a “hold” rating and set a $35.00 price objective (up previously from $34.00) on shares of Pfizer in a research note on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $37.61.

In other news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the sale, the insider now owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by corporate insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.